Phase 2 Co-PSMA trial shows 64Cu-SAR-bisPSMA PET/CT detected 63 prostate cancer lesions vs 24 with 68Ga-PSMA-11, with 78% vs 36% positive scans. Results changed management in 44% of patients.
PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07682584 |
Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis |
NOT_YET_RECRUITING | |
| NCT07655648 |
Dual-tracer PET Radiomics for Prostate Cancer Stratification |
COMPLETED |
